Tags

Type your tag names separated by a space and hit enter

Osteoprotegerin and mortality in hemodialysis patients with cardiovascular disease.
Clin Nephrol. 2013 Sep; 80(3):161-7.CN

Abstract

BACKGROUND

Patients treated with hemodialysis (HD) have an increased mortality, mainly caused by cardiovascular disease (CVD). Osteoprotegerin (OPG) is a glycoprotein involved in the regulation of the vascular calcification process. Previous studies have demonstrated that OPG is a prognostic marker of mortality. The aim of this study was to investigate if OPG was a prognostic marker of all-cause mortality in high-risk patients with end-stage renal disease and CVD.

METHODS

We prospectively followed 206 HD patients with CVD. OPG was measured at baseline and the patients were followed for 2 years or until reaching the primary endpoint, i.e., all-cause mortality.

RESULTS

All-cause mortality during follow-up was 44% (90/206). High OPG was associated with increased mortality, using the first tertile as reference, with an unadjusted HR of 1.70 (CI 1.00 - 2.88) for the second tertile and HR of 1.63 (CI 0.96 - 2.78) for the third tertile. In a multivariate Cox-regression analysis age, CRP and OPG in both the second and third tertile were significantly associated with increased mortality In the unadjusted survival analysis, a test for trend of OPG yielded a p-value of 0.08; in the adjusted analyses, the p-value for trend was 0.03.

CONCLUSIONS

In a high-risk population of hemodialysis patients with previously documented cardiovascular disease, a high level of OPG was an independent risk marker of all-cause mortality.

Authors

No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Multicenter Study
Randomized Controlled Trial
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

23547804

Citation

Winther, Simon, et al. "Osteoprotegerin and Mortality in Hemodialysis Patients With Cardiovascular Disease." Clinical Nephrology, vol. 80, no. 3, 2013, pp. 161-7.
Winther S, Christensen JH, Flyvbjerg A, et al. Osteoprotegerin and mortality in hemodialysis patients with cardiovascular disease. Clin Nephrol. 2013;80(3):161-7.
Winther, S., Christensen, J. H., Flyvbjerg, A., Schmidt, E. B., Jørgensen, K. A., Skou-Jørgensen, H., & Svensson, M. (2013). Osteoprotegerin and mortality in hemodialysis patients with cardiovascular disease. Clinical Nephrology, 80(3), 161-7. https://doi.org/10.5414/CN107803
Winther S, et al. Osteoprotegerin and Mortality in Hemodialysis Patients With Cardiovascular Disease. Clin Nephrol. 2013;80(3):161-7. PubMed PMID: 23547804.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Osteoprotegerin and mortality in hemodialysis patients with cardiovascular disease. AU - Winther,Simon, AU - Christensen,Jeppe Hagstrup, AU - Flyvbjerg,Allan, AU - Schmidt,Erik Berg, AU - Jørgensen,Kaj Anker, AU - Skou-Jørgensen,Hanne, AU - Svensson,My, PY - 2013/08/20/accepted PY - 2013/4/4/entrez PY - 2013/4/4/pubmed PY - 2013/12/19/medline SP - 161 EP - 7 JF - Clinical nephrology JO - Clin Nephrol VL - 80 IS - 3 N2 - BACKGROUND: Patients treated with hemodialysis (HD) have an increased mortality, mainly caused by cardiovascular disease (CVD). Osteoprotegerin (OPG) is a glycoprotein involved in the regulation of the vascular calcification process. Previous studies have demonstrated that OPG is a prognostic marker of mortality. The aim of this study was to investigate if OPG was a prognostic marker of all-cause mortality in high-risk patients with end-stage renal disease and CVD. METHODS: We prospectively followed 206 HD patients with CVD. OPG was measured at baseline and the patients were followed for 2 years or until reaching the primary endpoint, i.e., all-cause mortality. RESULTS: All-cause mortality during follow-up was 44% (90/206). High OPG was associated with increased mortality, using the first tertile as reference, with an unadjusted HR of 1.70 (CI 1.00 - 2.88) for the second tertile and HR of 1.63 (CI 0.96 - 2.78) for the third tertile. In a multivariate Cox-regression analysis age, CRP and OPG in both the second and third tertile were significantly associated with increased mortality In the unadjusted survival analysis, a test for trend of OPG yielded a p-value of 0.08; in the adjusted analyses, the p-value for trend was 0.03. CONCLUSIONS: In a high-risk population of hemodialysis patients with previously documented cardiovascular disease, a high level of OPG was an independent risk marker of all-cause mortality. SN - 0301-0430 UR - https://www.unboundmedicine.com/medline/citation/23547804/Osteoprotegerin_and_mortality_in_hemodialysis_patients_with_cardiovascular_disease_ L2 - http://www.dustri.com/nc/journals-in-english.html?artId=10531 DB - PRIME DP - Unbound Medicine ER -